Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia
Tóm tắt
Từ khóa
Tài liệu tham khảo
WHO. Diabetes mellitus. Fact Sheet N. 138, WHO information, 2002
Lucioni C, Garancini MP, Massi-Benedetti M, et al. The costs of type 2 diabetes mellitus in Italy. A CODE-2 Sub-Study. Treat Endocrinol 2003; 2(2): 121–33
UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352(9131): 854–65
Stratton IM, Adler AI, Neil H, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–12
UKPDS Group. UKPDS 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128(3): 165–75
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22(12): 1395–409
Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo controlled study. Am J Med 2001; 111(1): 10–7
Shaffer S, Rubin CJ, Zhu E. The effect of pioglitazone on the lipid profile in patients with type 2 diabetes. Diabetes 2000; 49 (Suppl. 1): A125
Coyle D, Lee KM, O’Brien BJ. The role of models within economic analysis. Focus on Type 2 Diabetes Mellitus. PharmacoEconomics 2002; 20 (Suppl. 1): 11–9
Palmer AJ, Weiss C, Brandt A, et al. Cost-effectiveness of intensive therapy for type 1 diabetes changes depending on risk factors and level of existing complications. Med Decis Making 1999; 17(4): 528
Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz Med Wochenschr 2000; 130(27–28): 1034–40
Hunt L. Pioglitazone the answer to managing type 2 DM in Europe? Pharmacoeconomics and Outcomes News 2001; 343: 7–9
Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. PharmacoEconomics 2002; 20 (Suppl. 1): 31–42
Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. PharmacoEconomics 2002; 20 (Suppl. 1): 43–53
Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Pt 2): 293–8
Wolf PA, D’Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22(3): 312–8
Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329(20): 1456–62
Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV The long-term incidence of macular edema. Ophthalmology 1995; 102(1): 7–16
Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77(14): 1179–94
Moss SE, Klein R, Klein BE. Long-term incidence of lower-extremity amputations in a diabetic population. Arch Fam Med 1996; 5(7): 391–8
Assmann G, Schulte H, Cullen P. New and classical risk factors. The Munster heart study (PROCAM). Eur J Med Res 1997; 2(6): 237–42
Molyneaux LM, Constantino MI, Mc Gill M, et al. Better glycaemic control and risk reduction of diabetic complications in Type 2 diabetes: comparison with the DCCT. Diabetes Res Clin Pract 1998; 42(2): 77–83
UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53
UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317(7160): 703–13
Palmer AJ, Neeser K, Paschen B, et al. Economic implications of the Total Ischaemic Burden Bisoprolol Study (TIBBS) follow-up. Journal of Medical Economics 1998; 1: 263–80
UKPDS Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). BMJ 1998; 317(7160): 713–20
UKPDS Group. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes (UKPDS 28). Diabetes Care 1998; 21(1): 87–92
Matthews DR, Cull CA, Stratton IM, et al. Sulphonylurea failure in non-insulin-dependent diabetic patients over six years (UKPDS 26). Diabet Med 1998; 15(4): 297–303
Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus (UKPDS 23). BMJ 1998; 316(7134): 823–8
Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281(21): 2005–12
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO.HOPE substudy. Lancet 2000; 355(9200): 253–9
Kshirsagar AV, Joy MS, Hogan SL, et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. Am J Kidney Dis 2000; 35(4): 695–707
Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (London) 2001; 101(6): 671–9
Ministero della Sanità. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera di cui al Decreto Ministeriale 14 dicembre 1994. Decreto Ministeriale 12 marzo 1997. Suppl. ord. alla G.U. n. 209, 8 settembre 1997
Ministero della Sanità. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitario Nazionale e relative tariffe. Decreto Ministeriale 22 luglio 1996. Suppl. ord. alla G.U. n. 216, 14 settembre 1996
Legge 18/1980 (Indennità di accompagnamento agli invalidi civili totalmente inabili), pubblicata su G.U. n. 44, 14 febbraio 1980
Porta M, Rizzitello A, Tomalino M, et al. Comparison of the cost-effectiveness of three approaches to screening for and treating sight-threatening diabetic retinopathy. Diabetes & Metabolism 1999; 25: 44–53
Lucioni C, Mazzi S, Serra G. L’autocontrollo del livello glicemico nei pazienti con diabete di tipo 2: i risultati dello studio CODE-2. Il Diabete, ottobre 1999
Cantagallo A. Costo-efficacia di un programma di prevenzione con dieta a basso contenuto proteico nella nefropatia diabetica. Mecosan 1999: 29: 9–17
Informatore Farmaceutico, marzo 2003 (aggiornamento). Milano; OEMF, 2003
Musacchio N, Lo Monaco G, Rocca A, et al. Razionalizzazione dell’erogazione dei presidi per diabetici in un distretto sociosanitario della Regione Lombardia. Giornale Italiano di Diabetologia 1998; 18: 157–60
IMS. Il mercato farmaceutico. Milano: IMS Health, 2002
Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15(3): 369–90
Gold MR (ed.), Siegel JE, Russel L, et al. Cost-effectiveness in Health and Medicine. New York; Oxford University Press, 1996
Goldman L, Garber AM, Grover SA, Hlatky MA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary heart disease events. Task Force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27(5): 1020–30
National Institute of Clinical Excellence. NICE Present Evidence to Health Select Committee. London; NICE, 2002